Discovery pro pbm contact number8/25/2023 Information you should consider before investing in our common stock. This summary highlights information contained elsewhere in this prospectus. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offeringĪnd the distribution of this prospectus applicable to that jurisdiction. No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that Is accurate only as of the date on the front cover page of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our The information contained in this prospectus We and the underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may Or on behalf of us or to which we have referred you. Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by Index to consolidated financial statements federal income tax consequences to non-U.S. Management's discussion and analysis of financial condition and results ofĬertain relationships and related party transactions Special note regarding forward-looking statements We intend to apply for listing of our common stock on the NASDAQ Global Market under the symbol "DOVA."Īre an "emerging growth company" as defined under the federal securities laws and will be subject to reduced public company reporting requirements. To this offering, there has been no public market for our common stock. TheĮstimated initial public offering price is between $ and $ per share. We are selling shares of our common stock. This is an initial public offering of shares of common stock by Dova Pharmaceuticals, Inc. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. These securities may not be sold until the registration statement filed with the Securities andĮxchange Commission is effective. The information in this preliminary prospectus is not complete and may be changed. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthĬompany. If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration Statement number of the earlier effective registration statement for the same offering. If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the SecuritiesĪct registration statement number of the earlier effective registration statement for the same offering. If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the Approximate date of commencement of proposed sale to the public:Īs soon as practicable after this Registration Statement is declared effective.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |